Orthocell Limited (ASX:OCC)
Australia · Delayed Price · Currency is AUD 1.330
+0.070 (5.56%)
Aug 15, 2025, 4:10 PM AEST
Orthocell Company Description
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia, the United States, the United Kingdom, and the European Union.
The company offers Ortho-ATI, a cell therapy for treatment of chronic tendon injuries; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental procedure; Remplir, a collagen scaffold used in peripheral nerve repair; and Ortho-ACI, an autologous chondrocyte implantation to treat articular cartilage defects in the knee and ankle.
Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.
Contact Details
Address: Building 191 Murdoch, 6150 Australia | |
| Phone | 61 8 9360 2888 |
| Website | orthocell.com |
Stock Details
| Ticker Symbol | OCC |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU000000OCC6 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Paul Frederick Anderson | Chief Executive Officer, MD and Executive Director |
| Alex McHenry | Chief Operating Officer |
| Prof. Ming Hao Zheng | Chief Scientific Officer and Member of Medical and Scientific Advisory Board |
| Tony Macintyre | Chief Technical Operations Officer |
| Adam Wood | Chief Commercial Officer |
| Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D. | Company Secretary |